ORCHID PHARMA
|
ORCHID PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 18.17 | 11.35 | -0.48 | -28.55 | -32.11 |
| CEPS(Rs) | 25.30 | 26.96 | 7.38 | 3.35 | 11.82 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 230.58 | 168.72 | 158.61 | 159.96 | 187.67 |
| Tax Rate(%) | -3.39 | - | - | - | - |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.52 | 12.66 | 9.75 | 11.26 | 6.24 |
| EBIT Margin(%) | 13.26 | 13.24 | -4.19 | -9.56 | -13.12 |
| Pre Tax Margin(%) | 11.22 | 8.30 | -10.17 | -21.16 | -14.41 |
| PAT Margin (%) | 11.60 | 8.30 | -10.17 | -21.16 | -14.41 |
| Cash Profit Margin (%) | 15.66 | 16.52 | 5.38 | 3.04 | 9.97 |
| Performance Ratios | |||||
| ROA(%) | 6.84 | 4.73 | -4.85 | -7.06 | -3.07 |
| ROE(%) | 10.23 | 8.27 | -8.75 | -13.43 | -225.00 |
| ROCE(%) | 9.35 | 9.11 | -2.32 | -3.53 | -3.29 |
| Asset Turnover(x) | 0.59 | 0.57 | 0.48 | 0.33 | 0.21 |
| Sales/Fixed Asset(x) | 0.65 | 0.56 | 0.48 | 0.37 | 0.35 |
| Working Capital/Sales(x) | 1.54 | 5.16 | 3.90 | 1.57 | 1.23 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.54 | 1.80 | 2.10 | 2.69 | 2.86 |
| Receivable days | 91.49 | 105.72 | 99.89 | 82.59 | 70.86 |
| Inventory Days | 109.80 | 110.01 | 106.18 | 119.45 | 117.49 |
| Payable days | 152.17 | 162.30 | 161.59 | 168.95 | 362.60 |
| Valuation Parameters | |||||
| PER(x) | 57.52 | 33.87 | - | - | - |
| PCE(x) | 41.32 | 14.26 | 38.52 | 736.19 | - |
| Price/Book(x) | 4.53 | 2.28 | 1.79 | 15.41 | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 6.31 | 2.81 | 2.54 | 23.32 | 0.90 |
| EV/Core EBITDA(x) | 36.42 | 18.03 | 22.34 | 159.31 | 7.95 |
| EV/EBIT(x) | 47.56 | 21.21 | -60.59 | -243.82 | -6.83 |
| EV/CE(x) | 3.96 | 1.83 | 1.55 | 9.49 | 0.33 |
| M Cap / Sales | 6.47 | 2.36 | 2.07 | 22.36 | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 23.05 | 19.00 | 24.33 | -6.97 | -19.36 |
| Core EBITDA Growth(%) | 36.82 | 63.14 | -3.48 | 20.95 | 965.63 |
| EBIT Growth(%) | 23.29 | 476.02 | 45.54 | 32.18 | -183.40 |
| PAT Growth(%) | 72.07 | 197.10 | 40.26 | -36.67 | -200.41 |
| EPS Growth(%) | 60.13 | 2,474.06 | 98.33 | 11.09 | -511.60 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | 0.48 | 0.41 | 0.69 | 0.74 |
| Current Ratio(x) | 3.04 | 1.35 | 1.60 | 3.02 | 3.25 |
| Quick Ratio(x) | 2.03 | 0.73 | 0.88 | 1.94 | 2.44 |
| Interest Cover(x) | 6.49 | 2.68 | -0.70 | -0.82 | -10.19 |
| Total Debt/Mcap(x) | 0.03 | 0.21 | 0.23 | 0.04 | - |
Compare Financial Ratios of peers of ORCHID PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ORCHID PHARMA | ₹9,080.6 Cr | 4.1% | 21.6% | 149.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,920.0 Cr | -0.1% | 1.7% | 45.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,160.0 Cr | -0.1% | -2.2% | 56.9% | Stock Analytics | |
| CIPLA | ₹118,917.0 Cr | 1.7% | 0.5% | 23.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,017.0 Cr | 5.7% | 12.4% | 18.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,997.1 Cr | -1.4% | 3.1% | 44.8% | Stock Analytics | |
ORCHID PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ORCHID PHARMA | 4.1% |
21.6% |
149.1% |
| SENSEX | -5% |
0.6% |
9.2% |
You may also like the below Video Courses
